Liver biopsy in children: Position paper of the ESPGHAN hepatology committee

Journal of Pediatric Gastroenterology and Nutrition

Volumn 60, Issue 3, 2015, Pages 408-420

  Dezsõfi, Antal ^a   Baumann, Ulrich ^b   Dhawan, Anil ^c   Durmaz, Ozlem ^d   Fischler, Bjorn ^e   Hadzic, Nedim ^c   Hierro, Loreto ^f   Lacaille, Florence ^g   McLin, Valerie A ^h   Nobili, Valerio ⁱ   Socha, Piotr ^j   Vajro, Pietro ^k   Knisely, Alexander S ^c  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c KING S COLLEGE HOSPITAL   (United Kingdom)

^d ISTANBUL UNIVERSITY   (Turkey)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f HOSPITAL INFANTIL LA PAZ   (Spain)

^g HÔPITAL NECKER ENFANTS MALADES   (France)

^h GENEVA UNIVERSITY HOSPITALS   (Switzerland)

ⁱ BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^j CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

^k UNIVERSITY OF SALERNO   (Italy)

more..

Author keywords

children; complications; contraindications; indications; liver biopsy; paediatric

Indexed keywords

ACUTE LIVER FAILURE; ALAGILLE SYNDROME; ALPHA1 ANTITRYPSIN STORAGE DISORDER; ARTERIOVENOUS FISTULA; ARTICLE; ASCITES; AUTOIMMUNE HEPATITIS; BILE LEAKAGE; BILIARY TRACT HEMORRHAGE; BLEEDING; BLOOD ANALYSIS; CHECKLIST; CHOLESTASIS; CHOLESTEROL ESTER STORAGE DISEASE; CHRONIC LIVER FAILURE; CONGENITAL DISORDER OF GLYCOSYLATION; CRYPTOGENIC HYPERTRANSAMINASEMIA; CYTOMEGALOVIRUS INFECTION; ECHOGRAPHY; EPSTEIN BARR VIRUS INFECTION; GENERAL ANESTHESIA; HEMATOCRIT; HEMATOTHORAX; HEMOGLOBIN BLOOD LEVEL; HEMOPHAGOCYTIC SYNDROME; HEPATITIS B; HEPATITIS C; HUMAN; HYPERTRANSAMINASEMIA; INFORMED CONSENT; INTRAHEPATIC CHOLESTASIS; LABORATORY DIAGNOSIS; LAPAROSCOPY; LAPAROTOMY; LIVER BIOPSY; LIVER DISEASE; LIVER EXAMINATION; LIVER HISTOLOGY; LIVER TRANSPLANTATION; LIVER TUMOR; LOCAL ANESTHESIA; MEDICAL EDUCATION; MEDLINE; MORTALITY; NEEDLE; NEONATAL CHOLESTASIS; NEWBORN DISEASE; PAIN; PATIENT POSITIONING; PEDIATRICS; PNEUMOTHORAX; PRIORITY JOURNAL; PROGNOSIS; PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS; SCLEROSING CHOLANGITIS; SEDATION; SICKLE CELL CRISIS; STORAGE DISEASE; THROMBOCYTOPENIA; TOXIC HEPATITIS; TRANSJUGULAR LIVER BIOPSY; VITAL SIGN; WILSON DISEASE; WOLMAN DISEASE; ADVERSE EFFECTS; BIOPSY; CHILD; CONTRAINDICATIONS; EUROPE; EVIDENCE BASED MEDICINE; GASTROENTEROLOGY; INFANT; LIVER; LIVER DISEASES; MEDICAL SOCIETY; NEWBORN; NUTRITIONAL SCIENCE; PATHOLOGY; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; PRESCHOOL CHILD; PROCEDURES; STANDARDS; TRENDS;

BIOPSY; CHILD; CHILD, PRESCHOOL; EUROPE; EVIDENCE-BASED MEDICINE; GASTROENTEROLOGY; HUMANS; INFANT; INFANT, NEWBORN; LIVER; LIVER DISEASES; NUTRITIONAL SCIENCES; PEDIATRICS; PRECISION MEDICINE; PROGNOSIS; SOCIETIES, MEDICAL;

EID: 84926420901     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0000000000000632     Document Type: Article

References (139)

1. Menghini G, Carnevali O, Orlandi F, et al. Clinical evaluation of liver biopsy: considerations on four year experiences. Prog Med (Napoli) 1953; 9: 1-10
2. Menghini G. One-second biopsy of the liver-problems of its clinical application. N Engl J Med 1970; 283: 582-5
3. Yang JG, Ma DQ, Peng Y, et al. Comparison of different diagnostic methods for differentiating biliary atresia from idiopathic neonatal hepatitis. Clin Imaging 2009; 33: 439-46
4. Russo P, Magee JC, Boitnott J, et al. Design and validation of the biliary atresia research consortium histologic assessment system for cholestasis in infancy. Clin Gastroenterol Hepatol 2011; 9: 357-62e2
5. Hartley J, Harnden A, Kelly D. Biliary atresia. BMJ 2010; 340: c2383
6. Azar G, Beneck D, Lane B, et al. Atypical morphologic presentation of biliary atresia and value of serial liver biopsies. J Pediatr Gastroenterol Nutr 2002; 34: 212-5
7. Bull LN, Carlton VE, Stricker NL, et al. Genetic and morphological findings in progressive familial intrahepatic cholestasis (Byler disease [PFIC-1] and Byler syndrome): evidence for heterogeneity. Hepatology 1997; 26: 155-64
8. Gonzales E, Gerhardt MF, Fabre M, et al. Oral cholic acid for hereditary defects of primary bile acid synthesis: a safe and effective long-Term therapy. Gastroenterology 2009; 137: 1310-20e1-3
9. Subramaniam P, Clayton PT, Portmann BC, et al. Variable clinical spectrum of the most common inborn error of bile acid metabolism- 3beta-hydroxy-Delta 5-C27-steroid dehydrogenase deficiency. J Pediatr Gastroenterol Nutr 2010; 50: 61-6
10. Melter M, Rodeck B, Kardorff R, et al. Progressive familial intrahepatic cholestasis: partial biliary diversion normalizes serum lipids and improves growth in noncirrhotic patients. Am J Gastroenterol 2000; 95: 3522-8
11. Kalicinski PJ, Ismail H, Jankowska I, et al. Surgical treatment of progressive familial intrahepatic cholestasis: comparison of partial external biliary diversion and ileal bypass. Eur J Pediatr Surg 2003; 13: 307-11
12. Emerick KM, Elias MS, Melin-Aldana H, et al. Bile composition in Alagille syndrome and PFIC patients having Partial external biliary diversion. BMC Gastroenterol 2008; 8: 47
13. Jacquemin E, De Vree JM, Cresteil D, et al. The wide spectrum of multidrug resistance 3 deficiency: from neonatal cholestasis to cirrhosis of adulthood. Gastroenterology 2001; 120: 1448-58
14. Chen HL, Chang PS, Hsu HC, et al. Progressive familial intrahepatic cholestasis with high gamma-glutamyltranspeptidase levels in Taiwanese infants: role of MDR3 gene defect?. Pediatr Res 2001; 50: 50-5
15. Colombo C, Vajro P, Degiorgio D, et al. Clinical features and genotype-phenotype correlations in children with progressive familial intrahepatic cholestasis type 3 related to ABCB4 mutations. J Pediatr Gastroenterol Nutr 2011; 52: 73-83
16. Anheim M, Chamouard P, Rudolf G, et al. Unexpected combination of inherited chorea-Acanthocytosis with MDR3 (ABCB4) defect mimicking Wilson's disease. Clin Genet 2010; 78: 294-5
17. Ramraj R, Finegold MJ, Karpen SJ. Progressive familial intrahepatic cholestasis type 3: overlapping presentation with Wilson disease. Clin Pediatr (Phila) 2012; 51: 689-91
18. Subramaniam P, Knisely A, Portmann B, et al. Diagnosis of Alagille syndrome-25 years of experience at King's College Hospital. J Pediatr Gastroenterol Nutr 2011; 52: 84-9
19. Lykavieris P, Hadchouel M, Chardot C, et al. Outcome of liver disease in children with Alagille syndrome: a study of 163 patients. Gut 2001; 49: 431-5
20. Bakula A, Socha P, Pawlowska J, et al. Good and bad prognosis of alpha-1-Antitrypsin deficiency in children: when to list for liver transplantation. Transplant Proc 2007; 39: 3186-8
21. Francavilla R, Castellaneta SP, Hadzic N, et al. Prognosis of alpha-1-Antitrypsin deficiency-related liver disease in the era of paediatric liver transplantation. J Hepatol 2000; 32: 986-92
22. Squires RH Jr, Shneider BL, Bucuvalas J, et al. Acute liver failure in children: the first 348 patients in the pediatric acute liver failure study group. J Pediatr 2006; 148: 652-8
23. Lee WM, Squires RH Jr, Nyberg SL, et al. Acute liver failure: summary of a workshop. Hepatology 2008; 47: 1401-15
24. Dhawan A, Cheeseman P, Mieli-Vergani G. Approaches to acute liver failure in children. Pediatr Transplant 2004; 8: 584-8
25. Lee D, Chitturi S, Kench J, et al. Transjugular liver biopsy effecting changes in clinical management. Australas Radiol 2003; 47: 117-20
26. Hind JMQA, Taylor RM, Kortsalioudakis C, et al. Role of liver histology in the management of acute liver failure in children. Hepatology 2007; 46 (S1): 725A-821A.
27. Miraglia R, Luca A, Gruttadauria S, et al. Contribution of transjugular liver biopsy in patients with the clinical presentation of acute liver failure. Cardiovasc Intervent Radiol 2006; 29: 1008-10
28. Habdank K, Restrepo R, Ng V, et al. Combined sonographic and fluoroscopic guidance during transjugular hepatic biopsies performed in children: a retrospective study of 74 biopsies. AJR Am J Roentgenol 2003; 180: 1393-8
29. Iorio R, Sepe A, Giannattasio A, et al. Hypertransaminasemia in childhood as a marker of genetic liver disorders. J Gastroenterol 2005; 40: 820-6
30. Boldrini R, Devito R, Biselli R, et al. Wolman disease and cholesteryl ester storage disease diagnosed by histological and ultrastructural examination of intestinal and liver biopsy. Pathol Res Pract 2004; 200: 231-40
31. Patrick AD, Willcox P, Stephens R, et al. Prenatal diagnosis of Wolman's disease. J Med Genet 1976; 13: 49-51
32. Hamilton J, Jones I, Srivastava R, et al. A new method for the measurement of lysosomal acid lipase in dried blood spots using the inhibitor Lalistat 2. Clin Chim Acta 2012; 413: 1207-10
33. Vajro P, Lenta S, Socha P, et al. Diagnosis of nonalcoholic fatty liver disease in children and adolescents: position paper of the ESPGHAN Hepatology Committee. J Pediatr Gastroenterol Nutr 2012; 54: 700-13
34. Mieli-Vergani G, Heller S, Jara P, et al. Autoimmune hepatitis. J Pediatr Gastroenterol Nutr 2009; 49: 158-64
35. Ferenci P, Caca K, Loudianos G, et al. Diagnosis and phenotypic classification of Wilson disease. Liver Int 2003; 23: 139-42
36. Dhawan A, Taylor RM, Cheeseman P, et al. Wilson's disease in children: 37-year experience and revised King's score for liver transplantation. Liver Transpl 2005; 11: 441-8
37. Fontana RJ, Seeff LB, Andrade RJ, et al. Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology 2010; 52: 730-42
38. Suzuki A, Brunt EM, Kleiner DE, et al. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology 2011; 54: 931-9
39. Watkins PB, Seeff LB. Drug-induced liver injury: summary of a single topic clinical research conference. Hepatology 2006; 43: 618-31
40. Wang SZ, Gao S, Liu YM, et al. Clinical characteristics of druginduced liver injury in 31 pediatric cases. Zhonghua Gan Zang Bing Za Zhi 2012; 20: 193-5
41. Devarbhavi H, Karanth D, Prasanna KS, et al. Drug-Induced liver injury with hypersensitivity features has a better outcome: a singlecenter experience of 39 children and adolescents. Hepatology 2011; 54: 1344-50
42. LaRusso NF, Shneider BL, Black D, et al. Primary sclerosing cholangitis: summary of a workshop. Hepatology 2006; 44: 746-64
43. de Lonlay P, Seta N, Barrot S, et al. A broad spectrum of clinical presentations in congenital disorders of glycosylation I: a series of 26 cases. J Med Genet 2001; 38: 14-9
44. Mandato C, Brive L, Miura Y, et al. Cryptogenic liver disease in four children: a novel congenital disorder of glycosylation. Pediatr Res 2006; 59: 293-8
45. Gunay-Aygun M, Avner ED, Bacallao RL, et al. Autosomal recessive polycystic kidney disease and congenital hepatic fibrosis: summary statement of a first National Institutes of Health/Office of Rare Diseases conference. J Pediatr 2006; 149: 159-64
46. Jonas MM, Mizerski J, Badia IB, et al. Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J Med 2002; 346: 1706-13
47. Jara P, Bortolotti F. Interferon-Alpha treatment of chronic hepatitis B in childhood: a consensus advice based on experience in European children. J Pediatr Gastroenterol Nutr 1999; 29: 163-70
48. Bortolotti F, Verucchi G, Camma C, et al. Long-Term course of chronic hepatitis C in children: from viral clearance to end-stage liver disease. Gastroenterology 2008; 134: 1900-7
49. Sokal EM, Bourgois A, Stephenne X, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in children and adolescents. J Hepatol 2010; 52: 827-31
50. Guido M, Bortolotti F, Leandro G, et al. Fibrosis in chronic hepatitis C acquired in infancy: is it only a matter of time?. Am J Gastroenterol 2003; 98: 660-3
51. Paya CV, Holley KE, Wiesner RH, et al. Early diagnosis of cytomegalovirus hepatitis in liver transplant recipients: role of immunostaining, DNA hybridization and culture of hepatic tissue. Hepatology 1990; 12: 119-26
52. Koch DG, Christiansen L, Lazarchick J, et al. Posttransplantation lymphoproliferative disorder-The great mimic in liver transplantation: appraisal of the clinicopathologic spectrum and the role of Epstein-Barr virus. Liver Transpl 2007; 13: 904-12
53. Barkholt L, Reinholt FP, Teramoto N, et al. Polymerase chain reaction and in situ hybridization of Epstein-Barr virus in liver biopsy specimens facilitate the diagnosis of EBV hepatitis after liver transplantation. Transpl Int 1998; 11: 336-44
54. Nuckols JD, Baron PW, Stenzel TT, et al. The pathology of liverlocalized post-Transplant lymphoproliferative disease: a report of three cases and a review of the literature. Am J Surg Pathol 2000; 24: 733-41
55. Czauderna P, Mackinlay G, Perilongo G, et al. Hepatocellular carcinoma in children: results of the first prospective study of the International Society of Pediatric Oncology group. J Clin Oncol 2002; 20: 2798-804
56. Ovchinsky N, Moreira RK, Lefkowitch JH, et al. Liver biopsy in modern clinical practice: a pediatric point-of-view. Adv Anat Pathol 2012; 19: 250-62
57. Hubscher S. What does the long-Term liver allograft look like for the pediatric recipient?. Liver Transpl 2009; 15 (suppl 2): S19-24
58. Berenguer M, Rayon JM, Prieto M, et al. Are posttransplantation protocol liver biopsies useful in the long term?. Liver Transpl 2001; 7: 790-6
59. Mells G, Mann C, Hubscher S, et al. Late protocol liver biopsies in the liver allograft: a neglected investigation?. Liver Transpl 2009; 15: 931-8
60. Miyagawa-Hayashino A, Yoshizawa A, Uchida Y, et al. Progressive graft fibrosis and donor-specific human leukocyte antigen antibodies in pediatric late liver allografts. Liver Transpl 2012; 18: 1333-42
61. Ekong UD. The long-Term liver graft and protocol biopsy: do we want to look?. What will we find?. Curr Opin Organ Transplant 2011; 16: 505-8
62. Demetris A. Importance of liver biopsy findings in immunosuppression management: biopsy monitoring and working criteria for patients with operational tolerance. Liver Transpl 2012; 18: 1154-70
63. Rockey DC, Caldwell SH, Goodman ZD, et al. Liver biopsy. Hepatology 2009; 49: 1017-44
64. Lindor KD, Bru C, Jorgensen RA, et al. The role of ultrasonography and automatic-needle biopsy in outpatient percutaneous liver biopsy. Hepatology 1996; 23: 1079-83
65. Siegel CA, Silas AM, Suriawinata AA, et al. Liver biopsy 2005: when and how?. Cleve Clin J Med 2005; 72: 199-20106, 08 passim
66. Lebrec D, Goldfarb G, Degott C, et al. Transvenous liver biopsy: an experience based on 1000 hepatic tissue samplings with this procedure. Gastroenterology 1982; 83: 338-40
67. McAfee JH, Keeffe EB, Lee RG, et al. Transjugular liver biopsy. Hepatology 1992; 15: 726-32
68. Smith TP, Presson TL, Heneghan MA, et al. Transjugular biopsy of the liver in pediatric and adult patients using an 18-gauge automated core biopsy needle: a retrospective review of 410 consecutive procedures. AJR Am J Roentgenol 2003; 180: 167-72
69. Esposito C, Garipoli V, Vecchione R, et al. Laparoscopy-guided biopsy in diagnosis of liver disorders in children. Liver 1997; 17: 288-92
70. Vajro P, Hadchouel P, Hadchouel M, et al. Incidence of cirrhosis in children with chronic hepatitis. J Pediatr 1990; 117: 392-6
71. Esposito C, Garipoli V, Pasquale M, et al. Percutaneous blind needle biopsy versus combined laparoscopic excisional and guided needle biopsy in the diagnosis of liver disorders in pediatric patients. Ital J Gastroenterol Hepatol 1997; 29: 179-81
72. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001; 344: 495-500
73. Sporea I, Popescu A, Sirli R. Why, who and how should perform liver biopsy in chronic liver diseases.World J Gastroenterol 2008; 14: 3396-402
74. El-Shabrawi MH, El-Karaksy HM, Okahsa SH, et al. Outpatient blind percutaneous liver biopsy in infants and children: is it safe?. Saudi J Gastroenterol 2012; 18: 26-33
75. Palmer T, Georgiades I, Treanor D, et al. Improved tissue sections for medical liver biopsies: a comparison of 16 vs 18 g biopsy needles using digital pathology. J Clin Pathol 2014; 67: 415-9
76. Grant A, Neuberger J. Guidelines on the use of liver biopsy in clinical practice. British Society of Gastroenterology. Gut 1999; 45 (suppl 4): IV1-1
77. Maharaj B, Bhoora IG. Complications associated with percutaneous needle biopsy of the liver when one, two or three specimens are taken. Postgrad Med J 1992; 68: 964-7
78. Linder H. Grenzen und Gefahren der perkutanen Leberbiopsie mit der Menghini-Nadel: Erfahrungen bei 80, 000 Leberbiopsien. Dtsch Med Wochenschr 1967; 92: 1751-7
79. Pietrobattista A, Fruwirth R, Natali G, et al. Is juvenile liver biopsy unsafe?. Putting an end to a common misapprehension. Pediatr Radiol 2009; 39: 959-61
80. Piccinino F, Sagnelli E, Pasquale G, et al. Complications following percutaneous liver biopsy. A multicentre retrospective study on 68, 276 biopsies. J Hepatol 1986; 2: 165-73
81. van Leeuwen DJ, Wilson L, Crowe DR. Liver biopsy in the mid-1990s: questions and answers. Semin Liver Dis 1995; 15: 340-59
82. Garcia-Tsao G, Boyer JL. Outpatient liver biopsy: how safe is it?. Ann Intern Med 1993; 118: 150-3
83. Janes CH, Lindor KD. Outcome of patients hospitalized for complications after outpatient liver biopsy. Ann Intern Med 1993; 118: 96-8
84. Gonzalez-Vallina R, Alonso EM, Rand E, et al. Outpatient percutaneous liver biopsy in children. J Pediatr Gastroenterol Nutr 1993; 17: 370-5
85. Perrault J, McGill DB, Ott BJ, et al. Liver biopsy: complications in 1000 inpatients and outpatients. Gastroenterology 1978; 74: 103-6
86. Sherlock S, Dick R, Van Leeuwen DJ. Liver biopsy today. The Royal Free Hospital experience. J Hepatol 1985; 1: 75-85
87. Stone MA, Mayberry JF. An audit of ultrasound guided liver biopsies: a need for evidence-based practice. Hepatogastroenterology 1996; 43: 432-4
88. McGill DB, Rakela J, Zinsmeister AR, et al. A 21-year experience with major hemorrhage after percutaneous liver biopsy. Gastroenterology 1990; 99: 1396-400
89. Cohen MB, HH AK, Lambers D, et al. Complications of percutaneous liver biopsy in children. Gastroenterology 1992; 102: 629-32
90. Hoffer FA. Liver biopsy methods for pediatric oncology patients. Pediatr Radiol 2000; 30: 481-8
91. Westheim BH, Ostensen AB, Aagenaes I, et al. Evaluation of risk factors for bleeding after liver biopsy in children. J Pediatr Gastroenterol Nutr 2012; 55: 82-7
92. Eisenberg E, Konopniki M, Veitsman E, et al. Prevalence and characteristics of pain induced by percutaneous liver biopsy. Anesth Analg 2003; 96: 1392-6
93. Hurwitz LM, Thompson WM. Calcified hepatic arteriovenous fistula found after biopsy of the liver: unusual cause of calcification in the right upper quadrant. AJR Am J Roentgenol 2002; 179: 1293-5
94. Hashimoto E, Ludwig J, MacCarty RL, et al. Hepatoportal arteriovenous fistula: morphologic features studied after orthotopic liver transplantation. Hum Pathol 1989; 20: 707-9
95. Otobe Y, Hashimoto T, Shimizu Y, et al. Formation of a fatal arterioportal fistula following needle liver biopsy in a child with a living-related liver transplant: report of a case. Surg Today 1995; 25: 916-9
96. Jabbour N, Reyes J, Zajko A, et al. Arterioportal fistula following liver biopsy. Three cases occurring in liver transplant recipients. Dig Dis Sci 1995; 40: 1041-4
97. Falkenstein K, Flynn L, Dunn S, et al. Arterial-venous fistulas following pediatric liver transplant case studies. Pediatr Transplant 2007; 11: 683-8
98. Kalambokis G, Manousou P, Vibhakorn S, et al. Transjugular liver biopsy-indications, adequacy, quality of specimens, and complications- A systematic review. J Hepatol 2007; 47: 284-94
99. van der Poorten D, Kwok A, Lam T, et al. Twenty-year audit of percutaneous liver biopsy in a major Australian teaching hospital. Intern Med J 2006; 36: 692-9
100. Smith TP, McDermott VG, Ayoub DM, et al. Percutaneous transhepatic liver biopsy with tract embolization. Radiology 1996; 198: 769-74
101. Gilmore IT, Burroughs A, Murray-Lyon IM, et al. Indications, methods, and outcomes of percutaneous liver biopsy in England andWales: an audit by the British Society of Gastroenterology and the Royal College of Physicians of London. Gut 1995; 36: 437-41
102. Livraghi T, Lombardi C, Mascia G. Bile peritonitis: another complication after fine-needle biopsy. Diagn Imaging 1983; 52: 33-5
103. Clark RA, Frey RT, Colley DP, et al. Transcatheter embolization of hepatic arteriovenous fistulas for control of hemobilia. Gastrointest Radiol 1981; 6: 353-6
104. Bubak ME, Porayko MK, Krom RA, et al. Complications of liver biopsy in liver transplant patients: increased sepsis associated with choledochojejunostomy. Hepatology 1991; 14: 1063-5
105. Amaral JG, Schwartz J, Chait P, et al. Sonographically guided percutaneous liver biopsy in infants: a retrospective review. AJR Am J Roentgenol 2006; 187: W644-9
106. Tobin MV, Gilmore IT. Plugged liver biopsy in patients with impaired coagulation. Dig Dis Sci 1989; 34: 13-5
107. Little AF, Ferris JV, Dodd GD 3rd et al. Image-guided percutaneous hepatic biopsy: effect of ascites on the complication rate. Radiology 1996; 199: 79-83
108. Atar E, Ben Ari Z, Bachar GN, et al. A comparison of transjugular and plugged-percutaneous liver biopsy in patients with contraindications to ordinary percutaneous liver biopsy and an ''in-house'' protocol for selecting the procedure of choice. Cardiovasc Intervent Radiol 2010; 33: 560-4
109. Sawyerr AM, McCormick PA, Tennyson GS, et al. A comparison of transjugular and plugged-percutaneous liver biopsy in patients with impaired coagulation. J Hepatol 1993; 17: 81-5
110. Kamphuisen PW, Wiersma TG, Mulder CJ, et al. Plugged-percutaneous liver biopsy in patients with impaired coagulation and ascites. Pathophysiol Haemost Thromb 2002; 32: 190-3
111. Sterling RPD, Post T, Herberger T, et al. Increasing size of true cut needle is associated with increased bleeding in porcine liver biopsies. Hepatology 1995; 22: 694A.
112. Lykavieris P, Crosnier C, Trichet C, et al. Bleeding tendency in children with Alagille syndrome. Pediatrics 2003; 111: 167-70
113. Mannucci PM, Remuzzi G, Pusineri F, et al. Deamino-8-D-Arginine vasopressin shortens the bleeding time in uremia. N Engl J Med 1983; 308: 8-12
114. Remuzzi G, Pusineri F. Coagulation defects in uremia. Kidney Int Suppl 1988; 24: S13-7
115. Gissen P, Tee L, Johnson CA, et al. Clinical and molecular genetic features of ARC syndrome. Hum Genet 2006; 120: 396-409
116. Azzam RK, Alonso EM, Emerick KM, et al. Safety of percutaneous liver biopsy in infants less than three months old. J Pediatr Gastroenterol Nutr 2005; 41: 639-43
117. Tripodi A, Chantarangkul V, Primignani M, et al. Point-of-care coagulation monitors calibrated for the international normalized ratio for cirrhosis (INRliver) can help to implement the INRliver for the calculation of the MELD score. J Hepatol 2009; 51: 288-95
118. Ewe K. Bleeding after liver biopsy does not correlate with indices of peripheral coagulation. Dig Dis Sci 1981; 26: 388-93
119. Tripodi A, Chantarangkul V, Primignani M, et al. The international normalized ratio calibrated for cirrhosis (INR(liver)) normalizes prothrombin time results for model for end-stage liver disease calculation. Hepatology 2007; 46: 520-7
120. Pettersson M, Fischler B, Petrini P, et al. Recombinant FVIIa in children with liver disease. Thromb Res 2005; 116: 185-97
121. Brown JB, Emerick KM, Brown DL, et al. Recombinant factor VIIa improves coagulopathy caused by liver failure. J Pediatr Gastroenterol Nutr 2003; 37: 268-72
122. Boberg KM, Brosstad F, Egeland T, et al. Is a prolonged bleeding time associated with an increased risk of hemorrhage after liver biopsy?. Thromb Haemost 1999; 81: 378-81
123. Oshrine B, Lehmann LE, Duncan CN. Safety and utility of liver biopsy after pediatric hematopoietic stem cell transplantation. J Pediatr Hematol Oncol 2011; 33: e92-7
124. Zakaria N, Knisely A, Portmann B, et al. Acute sickle cell hepatopathy represents a potential contraindication for percutaneous liver biopsy. Blood 2003; 101: 101-3
125. Rungsinaporn K, Phaisakamas T. Frequency of abnormalities detected by upper abdominal ultrasound. J Med Assoc Thai 2008; 91: 1072-5
126. Lee SE, Kim HY, Jung SE, et al. Situs anomalies and gastrointestinal abnormalities. J Pediatr Surg 2006; 41: 1237-42
127. Kelly D. Differential diagnosis and useful investigations. In: Kelly D, ed. Diseases of the Liver and Biliary System in Children, 3rd ed. Oxford: Blackwell Publishing; 2008: 21-34
128. Pietrobattista A, Alterio A, Natali G, et al. Needle biopsy in children with liver diseases. In: Mizuguchi Y, ed. Liver Biopsy in Modern Medicine. Rijeka, Croatia: InTech; 2011
129. Sharma P, McDonald GB, Banaji M. The risk of bleeding after percutaneous liver biopsy: relation to platelet count. J Clin Gastroenterol 1982; 4: 451-3
130. Alagille D, Odievre M. Maladies du Foie et des Voies Biliaires chez l'Enfant. Paris: Flammarion Medicine Sciences; 1978
131. Ratziu V, Charlotte F, Heurtier A, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 128: 1898-906
132. UC San Diego Health Sciences, Hepatology Liver Biopsy Guidelines. http://gastro.ucsd.edu/liver/Documents/Liver%20Biopsy%20Guidelines. pdf. Accessed September 1, 2014
133. Rudolph CD, Winter HS, et al., NASPGN Executive Council NT. NASPGN guidelines for training in pediatric gastroenterology. J Pediatr Gastroenterol Nutr 1999; 29: S1-26
134. American Association for the Study of Liver Diseases; American College of Gastroenterology; American Gastroenterological Association; American Society for Gastrointestinal Endoscopy. Training the gastroenterologist of the future: the Gastroenterology Core Curriculum. Gastroenterology 2003; 124: 1055-104
135. Shah S, Mayberry JF, Wicks ACB, et al. Liver biopsy under ultrasound control: implications for training in the Calman era. Gut 1999; 45: 628-9
136. Westheim BH, Aagenaes I, Ostensen AB, et al. Effect of operator experience and frequency of procedure performance on complication rate after ultrasound-guided percutaneous liver biopsies. J Pediatr Gastroenterol Nutr 2013; 57: 638-43
137. Gunneson TJ, Menon KV, Wiesner RH, et al. Ultrasound-Assisted percutaneous liver biopsy performed by a physician assistant. Am J Gastroenterol 2002; 97: 1472-5
138. Riley TR 3rd. How often does ultrasound marking change the liver biopsy site?. Am J Gastroenterol 1999; 94: 3320-2
139. Peppercorn J, Shapira I, Deshields T, et al. Ethical aspects of participation in the Database of Genotypes and Phenotypes of the National Center for Biotechnology Information: the Cancer and Leukemia Group B Experience. Cancer 2012; 118: 5060-8